Search clinical trials for: New oral anticoagulant

Total 87573 results

Janssen Scientific Affairs, LLC
Bayer

Completed

Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants

Pharmacokinetics | Healthy Participants | Bioavailability

United States
University of Hohenheim
German Federal Ministry of Education and Research

Completed

Improved Oral Bioavailability of Curcumin Incorporated Into Micelles

Pharmacokinetics of New Curcumin Formulations | Safety of New Curcumin Formulations

Germany
Assistance Publique - Hôpitaux de Paris

Unknown

Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF) (Presage-Aco)

Non Valvular Atrial Fibrillation (nv AF)
AiCure
Montefiore Medical Center

Completed

Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy.

Stroke

United States
National Heart, Lung, and Blood Institute (NHLBI)
Bristol-Myers Squibb

Completed

Clarification of Optimal Anticoagulation Through Genetics (COAG)

Stroke | Venous Thrombosis | Atrial Fibrillation | Atrial Flutter

United States
Takeda

Completed

Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement

Venous Thromboembolism

United States, Canada
Sanofi

Terminated

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation (BOREALIS-AF)

Atrial Fibrillation

South Africa, Thailand, Chile, Guatemala, Ukraine, United States, Argentina, Australia, Austria, Belarus, Brazil, Bulgaria, Canada, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Greece, India, ... and more
United Therapeutics

Completed

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies (Aspire)

Pulmonary Arterial Hypertension

United States
Clark Bishop

Completed

Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients

Cystic Fibrosis

Italy
Northwell Health
Staten Island University Hospital

Completed

The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

Osteoporosis

United States
Private Hospital Heart Center Varde

Completed

Safe Use of New Oral Anticoagulants in Ablation for Atrial Fibrillation

Atrial Fibrillation
Kyunghee University Medical Center

Unknown

Pleotropic Effect of New Oral Anticoagulants

Atrial Fibrillation

Korea, Republic of
Ferring Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females

Infertility

United States
University Hospital Heidelberg

Completed

Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot) (RASUNOA)

Ischemic Stroke | Intracranial Hemorrhage

Germany
Northwestern University
National Cancer Institute (NCI)

Completed

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ

Estrogen Receptor-positive Breast Cancer | Ductal Breast Carcinoma in Situ

United States
Bayer
Janssen Research & Development, LLC

Completed

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion (X-VERT)

Atrial Fibrillation

Belgium, France, Spain, China, Italy, United States, Canada, South Africa, Portugal, Singapore, Germany, Greece, Netherlands, United Kingdom, Brazil, Denmark, Finland
Bayer

Completed

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

Venous Thromboembolism

United States, Canada
Swedish Orphan Biovitrum

Completed

Study to Characterize the Effect of Heparin on Palifermin Activity

Oral Mucositis

United States
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Venous Thromboembolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, New Zealand, Poland, India, United States, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Taiwan, Brazil, Denmark, German... and more
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis

Venous Thromboembolism

France, Italy, Czech Republic, Canada, Netherlands, Australia, United States, Poland, South Africa, Sweden, Israel, Denmark, Brazil
Sheba Medical Center

Unknown

Therapy With New Oral Anticoagulants

Atrial Fibrillation | Non-valvular Atrial Fibrillation

Israel
Xijing Hospital

Unknown

Edoxaban for TIA and Acute Minor Stroke

Ischemia | Stroke | Cerebral Infarction

China
Johann Wolfgang Goethe University Hospital

Completed

Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study

Clot Formation and Platelet Aggregation in Point of Care Testing

Germany
Boehringer Ingelheim

Terminated

Dabigatran Etexilate in Patients With Mechanical Heart Valves (RE-ALIGN)

Heart Valve Diseases

Belgium, Canada, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Poland, Sweden
Boehringer Ingelheim

Terminated

Follow on Study From RE-ALIGN

Thromboembolism | Heart Valve Prosthesis

Belgium, Canada, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Poland
Boehringer Ingelheim

Completed

Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE (RE-SONATE)

Venous Thromboembolism

United States, Australia, Austria, Belgium, Canada, Czech Republic, Estonia, Germany, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Russian Federation, Singapore, South Africa, Sweden, Switzer... and more
Boehringer Ingelheim

Completed

Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (RE-COVER I)

Thromboembolism

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Netherlands, New Zealand, Norway, Portugal, Russian Federation, Slovakia, South... and more
Boehringer Ingelheim

Completed

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE) (RE-COVER II)

Thromboembolism

United States, Australia, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, France, Hungary, India, Israel, Italy, Korea, Republic of, Malaysia, Netherlands, New Zealand, Norway, Philippines, Poland, Russian Federation, Si... and more
Cephalon

Completed

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Pain | Cancer | Sickle Cell Anemia | Severe Burns

United States, Canada, Puerto Rico
Hvidovre University Hospital

Completed

Reporting of Adverse Events in Patients Treated With New Oral Anticoagulants

Bleeding as Complication to Anticoagulation Therapy

Denmark
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

Pulmonary Embolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Switzerland, United States, New Zealand, Poland, India, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Estonia, Thailand, Brazil, Germany, Korea, Republic... and more
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Venous Thrombosis

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, United States, New Zealand, Poland, India, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Brazil, Denmark, Germany, Norw... and more
Xijing Hospital

Unknown

Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events (ADANCE)

Ischemic Stroke | TIA

China
Xijing Hospital

Unknown

Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events (TRACE)

Ischemic Stroke | TIA

China
Cancer Research Campaign Clinical Trials Centre

Completed

Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters

Thromboembolism

United Kingdom
Yale University

Completed

Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer

Breast Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer

Endometrial Cancer

United States, Canada
National Cancer Institute (NCI)

Completed

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Recurrent Prostate Cancer | Fallopian Tube Cancer | Bone Metastases | Lung Metastases | Stage III Renal Cell Cancer | Liver Metastases | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Inflammatory Breast Cancer | Metastatic Transitional Cell Cancer of the... and other conditions

United States
University of California, San Francisco
AtriCure, Inc.

Withdrawn

Study of Left Atrial Appendage Closure in Patients With Atrial Fibrillation - III (PLACE III)

Atrial Fibrillation

United States, Germany, Poland
Columbia University
National Center for Complementary and Integrative Health (NCCIH)

Terminated

Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer

Pancreatic Cancer | Malnutrition

United States
Icahn School of Medicine at Mount Sinai

Completed

Genetic Response to Warfarin in Healthy Subjects

Healthy

United States
Biosite

Completed

User Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity (ECLIPSE-02)

Oral Anticoagulation

United States
Southwest Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

S9630, Medroxyprogesterone in Treating Women With Breast Cancer

Breast Cancer | Endometrial Cancer

United States
Gines Escolar
Ministry of Health, Spain

Unknown

Reversal of the Antithrombotic Action of New Oral Anticoagulants (REVANT)

Hemorrhage | Thrombosis | Anticoagulant-induced Bleeding | Anticoagulant Overdosage

Spain
St. Joseph's Healthcare Hamilton
McMaster University

Completed

Oral Vitamin K for Warfarin Associated Coagulopathy

Thrombosis | Bleeding | Coagulation

Canada, Singapore, United States, Italy
Biosite

Completed

Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin) (ECLIPSE 03)

Coagulation

United States
Eli Lilly and Company

Completed

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide

Diabetes Mellitus, Type 2

United States, Puerto Rico
Bristol-Myers Squibb

Completed

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

Deep-Vein Thrombosis

Netherlands, Austria, Italy, South Africa, Israel, United States, France, Australia, Poland, Sweden, Czech Republic
Cosmo Technologies Ltd

Completed

Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy

Ulcerative Colitis
Centers for Disease Control and Prevention
US Department of Veterans Affairs

Completed

TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection

Tuberculosis

United States, Canada, Brazil, Spain

Search clinical trials for: New oral anticoagulant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations